Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Group 1 - The call includes forward-looking statements reflecting the company's perspective as of November 10, 2025 [1] - The company does not commit to updating or revising forward-looking statements unless legally required [1] Group 2 - Key personnel present include the Founder and CEO, Chief Medical Officer, and Chief Commercial Officer, along with leading experts in hyperinsulinism [2] - Dr. Mansa Krishnamurthy and Dr. Azeez Farooki are recognized experts in the field, contributing to the discussion on congenital hyperinsulinism and tumor-related endocrine complications [2]